Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9290804 | 0.82 | NPSR1 (0.40) | NPSR1PAOXALDH1A1SIGMAR1 | |
| SCHEMBL1489120 | 0.81 | — | — | |
| SCHEMBL11809610 | 0.79 | CA12 (0.45) | ALDH1A1 | |
| SCHEMBL9685012 | 0.76 | ALDH1A1 (0.41) | ALDH1A1CYP2C9HSD17B10 | |
| SCHEMBL1488882 | 0.75 | — | — | |
| SCHEMBL1489079 | 0.75 | — | — | |
| SCHEMBL6892591 | 0.74 | NPSR1 (0.41) | NPSR1NPC1RAB9APAOXALDH1A1 | |
| SCHEMBL235041 | 0.74 | SIGMAR1 (0.42) | NPSR1PAOXALDH1A1SIGMAR1 | |
| SCHEMBL6045423 | 0.71 | KCNH2 (0.44) | NPSR1PAOXALDH1A1SIGMAR1 | |
| SCHEMBL755822 | 0.71 | SIGMAR1 (0.41) | NPSR1PAOXALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| EP-2334670-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | Almirall S.A. (ES) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010043377-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177521-A1 | New 2-Amidothiadiazole Derivatives | Almirall, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200557-A1 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES | S1PR2, S1PR3, S1PR1 | NPSR1 121/4885NPC1 378/4885RAB9A 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.